Clonal development of bladder cancer and its relevance to the clinical potential of HLA antigen and TP53 based gene therapy

Cancer Surveys

Volumn 31, Issue , 1998, Pages 109-128

  Nouri, A M E ^a   Oliver, R T D ^a   Nargund, V H ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; METALLOPROTEINASE; TELOMERASE;

ADVANCED CANCER; ANGIOGENESIS; ANTIGEN ANTIBODY COMPLEX; BLADDER CANCER; CANCER EPIDEMIOLOGY; CELL ADHESION; CYTOGENETICS; EARLY CANCER; GENE THERAPY; HLA SYSTEM; HUMAN; IMMUNOSURVEILLANCE; PRIORITY JOURNAL; REVIEW;

CARCINOMA, RENAL CELL; GENE THERAPY; GENES, MHC CLASS I; GENES, P53; HLA-A ANTIGENS; HLA-B7 ANTIGEN; HUMANS; KIDNEY NEOPLASMS; NEOPLASM REGRESSION, SPONTANEOUS; NEOVASCULARIZATION, PATHOLOGIC; TELOMERASE; URINARY BLADDER NEOPLASMS;

EID: 0031832942     PISSN: 02612429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Bicknell D, Kuklamanis L, Hampson R, Bodmer W and Karran P (1996) Selection for beta(2)microglobulin mutilation in mismatch repair-defective colorectal carcinomas. Current Biology 6 1695-1697
2. Browning M, Petronzelli F, Bicknell D et al (1996) Mechanisms of loss of HLA Class-I expression on colorectal tumor cells. Tissue Antigens 47 364-371
3. Chan S-Y, Delius H, Halpern A and Bernard HU (1995) Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny and taxonomy. Journal of Virology 69 3074-3083
4. Clements VK, Baskar S, Armstrong TD and Ostrand-Rosenherg S (1992) Invariant chain alters the malignant phenotype of MHC class II tumour cells. Journal of Immunology 149 2391
5. Davies B, Waxman J, Wasan H et al et al (1993) Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Research 53 5365-5369
6. Dickson R and Lippman M (1997) Molecular biology of breast cancer, In: de Vita V, Hellman S and Rosenberg S (eds). Cancer: Principles and Practice of Oncology, 5th ed, pp 1541-1557, Lippincott-Raven, Philadelphia
7. Dolin P (1991) An epidemiological review of tobacco use and bladder cancer. Smoking Related Diseases 2 129-143
8. Elhilali M, Gleave M, Fradet Y et al (1997) Placebo-associated remissions in a multicenter randomized double blind trial of Interferon gamma Ib (rlFN-y) for the treatment of metastatic renal cell carcinoma (mRCC). Proceedings of the American Society of Clinical Oncology 16 [Abstract 1187]
9. Folkmann J (1990) What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute 82 4-6
10. Folkman J and Shing Y (1992) Angiogenesis. Journal of Biological Chemistry 267 10931-10934
11. Fricker J (1996) Hepatocellular carcinoma and p53 gene therapy. Molecular Medicine Today 2 361
12. Hollingsworth SJ, Darling D, Gaken J et al (1996) The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma. British Journal of Cancer 74 6-15
13. Huddart RA, Titley J, Robertson D, Williams GT, Horwich A and Cooper CS (1995) Programmed cell death in response to chemotherapeutic agents in human germ cell tumour lines. European Journal of Cancer 31A 739-746
14. Hui K, Grosveld F and Festenstein H (1984) Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated transformation. Nature 132 311
15. Hui K, Ang P, Huang L and Tay S (1997) Phase 1 study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic MHC-DNA-liposome complexes. Gene Therapy 4 783-790
16. Hui KM, Sim T, Foo TT and Oei AA (1989) Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. Journal of Immunology 143 3835-3843
17. Iles RK, Lee CL, Oliver RTD and Chard T (1990) Composition of intact hormone and free subunits in the human chorionic gonadotrophin-like material found in serum and urine of patients with carcinoma of the bladder. Clinical Endocrinology 32 355-364
18. Itaya T, Yamagiwa S, Okada F et al (1987) Xenogenization of a mouse lung carcinoma (3LL) by transfection with an allogeneic class I major histocompatibility complex gene (H-2Ld). Cancer Research 47 3136-3140
19. Ito N, Matsuda T, Kakchi Y et al (1990) Bladder cancer producing granulocyte colony stimulating factor. New England Journal of Medicine 323 1709-1710
20. Jaeger TM, Weidner N, Chew K et al (1995) Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. Journal of Urology 154 69-71
21. Kaempfer R, Gerez L, Farbstein H et al (1996) Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. Journal of Clinical Oncology 14 1778-1786
22. Kamata S, Kageyama Y, Yonese J and Oshima H (1996) Significant telomere reduction in human superficial transitional cell carcinoma. British Journal of Urology 78 704-708
23. Ko SC, Gotoh A, Thalmann GN et al (1996) Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Human Gene Therapy 7 1683-1691.
24. Kobayashi H (1979) Viral xenogenization of intact tumor cells. Advances in Cancer Research 30 279-299
25. Lacombe L, Dalbagni G, Zhang Z et al (1996) Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after Bacillus Calmette-Guerin therapy: correlation to clinical outcome. Journal of Clinical Oncology 14 2646-2652
26. Lazar V, Diez SG, Laurent A et al (1995) Expression of human chorionic gonadotropin beta subunit genes in superficial and invasive bladder carcinomas. Cancer Research 55 3735-3738
27. Lee SK and Oliver RTD (1978) Autologous leukaemia specific T-cell mediated lymphotoxicity in patients with acute myelogenous leukemia. Journal of Experimental Medicine 147 912-922
28. Lerner S and Skinner D (1996) Radical cystectomy for bladder cancer, In: Vogelzang N, Scardino P, Shipley W and Coffey D (eds). Comprehensive Textbook of Genitourinary Oncology, pp 442-463, Williams & Wilkins, Baltimore
29. Lindenmann J and Klein PA (1967) Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. Journal of Experimental Medicine 126 93-108
30. Liotta L (1986) Tumor invasion and metastasis. Cancer Research 46 1
31. List AF, Miller TP and Grogan TM (1993) Deficient tumor infiltrating T lymphocyte response in malignant lymphoma-relationship to HLA expression and host immunocompetence. Leukemia 7 398-403
32. Martin ME, Jenkins BJ, Zuk RJ, Oliver RTD and Baithune SI (1989) Human chorionic gonadotrophin expression and histological findings as predictors of response to radiotherapy in carcinoma of the bladder. Virchows Archiv A, Pathological Anatomy and Histopathology 414 273-277
33. Morin G (1989) The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59 521-529
34. Nabel G, Gordon D, Bishop D et al (1996) Transfer of allogeneic major histocompatibility complex and B-2 microglobulin genes with DNA-liposome complexes in human melanoma. Proceedings of the American Society of Clinical Oncologists. 15 [Abstract 575]
35. Nargund V, Yoshida K, Smith J et al (1996) Telomerase activity in transitional cell carcinoma; its implications for non-invasive detection of bladder cancer. British Journal of Urology 77 10-11
36. Neal DE, Marsh C, Bennett MK et al (1985) Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1 366-368
37. Nouri AME, Bergbaum A, Lederer E et al (1991) Paired tumour infiltrating lymphocyte (TIL) and tumour cell line from bladder cancer: a new approach to study tumour immunology in vitro. International Journal of Cancer 27 608-612
38. Nouri AME, Hussain RF, Santos AVLD, Gillott DJ and Oliver RTD (1992) Induction of MHC antigens by tumour cell lines in response to interferons. European Journal of Cancer 28 1110-1115
39. Nouri AME, Hussain FR and Oliver RTD (1994) The frequency of major histocompatibility complex antigen abnormalities in urological tumours and their correction by gene transfection or cytokine stimulation. Cancer Gene Therapy 1 119-123
40. Nouri AME and Oliver RTD (1997) Tetraploid arrest with overexpressed non-mutated p53 in germ cell cancers: relevance to that chemosensitivity and possible application in non-germ cell cancers. International Journal of Oncology 11 1367-1371
41. O'Brien T, Cranston D, Fuggle S, Bicknell R and Harris A (1995) Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Research 55 510-513
42. Ohigashi T, Tachibana M, Tazaki H and Nakamura K (1992) Bladder cancer cells express functional receptors for granulocyte-colony stimulating factor. Journal of Urology 147 283-286
43. Oliver RTD (1976) Histocompatibility matching and renal graft survival. Proceedings of the Royal Society of Medicine 69 531-534
44. Oliver RTD (1996) Epidemiology of testis cancer, In: Vogelzang N, Shipley W, Scardino P and Coffey D (eds). Comprehensive Textbook of Genitourinary Oncology, pp 923-931, Williams & Wilkins, Baltimore, Maryland
45. Oliver RTD (1997) Future trials in germ cell malignancy (GCM) of the testis. European Journal of Surgical Oncology 23 117-122
46. Oliver RTD and Lee SK (1978) Histocompatibility antigens and T cell responses to leukaemia antigens, In: Neth RCGR, Hofschneider PH and Mannweiler K (eds). Modern Trends in Human Leukaemia III, pp 377-379, Springer-Verlag, Berlin
47. Oliver RTD and Oliver J (1996) Endocrine hypothesis for declining sperm count and rising testis cancer incidence. Lancet 346 339-340
48. Oliver RTD, Blandy JP and Hope-Stone HF (1989a) Medical management in bladder cancer, In: Urological and Genital Cancer, pp 115-126, Blackwell Scientific Publications, Oxford
49. Oliver RTD, Nethersall ABW and Bottomley JM (1989b) Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. British Journal of Urology 63 128-131
50. Oliver RTD, Nouri AME, Crosby D et al (1989c) Biological significance of beta hCG, HLA and other membrane antigen expression on bladder tumours and their relationship to tumour infiltrating lymphocytes (TIL). Journal of Immunogenetics 16 381-390
51. Oliver RTD, Leahy M and Ong J (1995) Combined seminoma/non-seminoma should be considered as intermediate grade germ cell cancer (GCC). European Journal, of Cancer 31A 1392-1394
52. Ooestorhuis JW, Gillis AJM, van Putten WJL, Jong B and Looijenga LHJ (1993) Interphase cytogenetics of carcinoma in situ of the testis. European Journal of Urology 23 16-22
53. Peng HQ, Hogg D, Malkin D et al (1993) Mutations of the p53 gene do not occur in testis cancer. Cancer Research 53 3574-3578
54. Pugh R (1973) The pathology of cancer of the bladder: an editorial overview. Cancer 32 1267-1274
55. Rhyu M (1995) Telomeres, telomerase and immortality, Journal of the National Cancer Institute 87 884-894
56. Roth JA, Nguyen D, Lawrence DD et al (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Medicine 2 985-991
57. Rovere GQD, Oliver RTD, McCance DJ and Castro JE (1988) Development of bladder tumour containing IIPV type 11 DNA after renal transplantation. British Journal of Urology 62 36-38
58. Sarkis A, Bajorin D, Reuter V et al (1995) Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant M-VAC. Journal of Clinical Oncology 13 1384-1390
59. Schwartz D, Goldfinger N and Rotter V (1993) Expression of p53 protein in spermatogenesis is confined to the tetraploid pachytene primary spermatocytes. Oncogene 8 1487-1494
60. Slattery M, Robinson L, Schuman K et al (1989) Cigarette smoking and exposure to passive smoke are risk factors for cervical cancer. Journal of the American Medical Association 261 1593-1598
61. Soloway MS and Masters S (1980) Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer 46 1158-1163
62. Spruck C, Rideout W, Olumi A et al (1993) Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Research 53 1162-1166
63. Spruck CH, Ohneseit FF, Gonzalez-Zulueta M et al (1994) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Research 54 784-788
64. Tomlinson IP and Bodmer WF (1995) The HLA system and the analysis of multifactorial genetic disease. Trends in Genetics 11 493-498
65. Toshitani K, Brand V, Browning MJ et al (1996) Expression of a single-chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes. Proceedings of the National Academy of Sciences of the USA 93 236-240
66. Vanky F, Wang P, Patarroyo M and Klein E (1990) Expression of the adhesion molecule ICAM1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunology, Immunotherapy 31 19-27
67. Weldon TE and Soloway MS (1975) Susceptibility of urothelium to neoplastic cellular implantation. Urology 5 824-827
68. Wilson RW, Chenggis ML and Unger ER (1990) Longitudinal study of human papillomavirus infection of the female urogenital tract by in situ hybridization. Archives of Pathology and Laboratory Medicine 114 155-159
69. Yoshida K, Sugino T, Tahara H et al (1997) Telomerase activity in bladder carcinoma and its implications for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 79 362-369
70. Zarling JM, Raich PC, McKeough M and Bach FH (1976) Generation of cytotoxic lymphocytes in vitro against autologous human leukaemia cells. Nature 262 691-693
71. Zinkernagel RM and Doherty PC (1979) MIIC cytotoxic T cells: studies on biological role polymorphic major transplantation antigens determining T cell restriction specificity. Advanced Immunology 27 51